Natera, Inc. and Kupando Therapeutics Launch Phase 1 Study to Monitor ctDNA in Advanced Skin Cancers
AUSTIN, Texas, August 12, 2026 Natera, Inc. announced a new collaboration with Kupando Therapeutics to support a Phase 1...
MRD
Advertisement
Natera Submits Signatera to Japan PMDA for MIBC Approval
AUSTIN, Texas, August 5, 2026 Natera, Inc. has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
Natera Reports Signatera Superior to AMERK in MCC Monitoring
AUSTIN, Texas, July 22, 2026 Natera announced the publication of a prospective, multicenter study in JAMA Dermatology demonstrating that...
Haier Biomedical Unveils Digital Blood Management Platform
KUALA LUMPUR, Malaysia, July 21, 2026 Haier Biomedical showcased its next-generation Digital Blood Management Platform at the ISBT Congress...
Tempus to Acquire Personalis in $1.5B Precision Oncology Deal
CHICAGO, July 20, 2026 Tempus AI, Inc. has entered into a definitive agreement to acquire Personalis, Inc. in a...
Advertisements
Organon, Samsung Bioepis Strengthen Australia Biosimilar Portfolio
SYDNEY, Australia & INCHEON, South Korea, July 16, 2026 Organon and Samsung Bioepis have expanded their longstanding partnership through...
ARUP Launches First Clinical Spectral Flow MRD Assay
SALT LAKE CITY, July 20, 2026 ARUP Laboratories has introduced ARUP CLARISPECT™ Multiple Myeloma MRD by Spectral Flow Cytometry,...
Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
Hansa Biopharma Reports Positive Idefirix Results
LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...
TransCode Starts Phase 2a Trial for TTX-MC138
BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...
Advertisement
